AVITA Medical Formalizes Leadership with Appointment of Cary Vance as CEO

AVITA Medical, Inc. (RCEL) announced on Thursday that it has officially promoted Cary Vance to the position of Chief Executive Officer and President, effective immediately. The move formalizes a leadership transition that has been in progress for several months. Vance has been leading the therapeutic acute wound care company in an interim capacity since October 2025, stepping into the role following the departure of the previous chief executive during that same month. His promotion provides the company with leadership continuity and stability. In a concurrent leadership update, the company announced the appointment of Jan Reed as its Chair, also effective immediately. This restructuring of the executive and board leadership is intended to streamline the company's strategic direction. Market reaction to the news was modestly positive. In pre-market activity, shares of RCEL were trading at $4.31, representing a 1.89% increase on the Nasdaq. The appointment signals a conclusion to the interim leadership phase and a commitment to the current management trajectory.